News
2h
Zacks Investment Research on MSNSarepta to Report Q2 Earnings: What's in Store for the Stock?
We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As ...
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...
Dealmaker-In-Chief” Donald Trump has been “positively monomaniacal” about trade lately, marvels Freddy Gray at The Spectator.
Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.
22h
MyChesCo on MSNFDA Clears Path for Resumed Use of Elevidys Gene Therapy in Ambulatory DMD Patients
The U.S. Food and Drug Administration (FDA) has recommended lifting the voluntary clinical hold on Elevidys for ambulatory patients with Duchenne Muscular Dystrophy (DMD), following a thorough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results